The Leukemia & Lymphoma Society (LLS) has recently developed a new grant concept to facilitate innovations in research and science. "The New Idea Award" grant concept funds untested treatment paradigms that are safer, more effective and substantically different from current therapies. Because these types of treatment are less likely to be funded by the traditional grants administered by the National Cancer Institute, the New Idea Award grant is crucial to ensuring the delivery of novel treatments and ultimately cures for more patients with blood cancers.
Applicants interested in the New Idea Award submit their innovative idea or approach as well as a method for testing it within the one-year grant period. Grants will be awarded up to $100,000 for the first year, after which applicants will be evaluated on the extent to which their innovative concept was substantiated based on initial testing. LLS plans to fund up to eight awards this first year and hopes that each new idea will help with the clinical advancement of cancer treatments.
A volunteer panel of researchers who are leaders in blood cancer treatment and research, chaired by Armand Keating, MD, Director of the Division of Hematology at the Institute of Biomaterials and Biomedical Engineering at the University of Toronto, will peer-review all grant applications. Panelists initially screened more than 100 applications and selected three dozen for review. After closely evaluating all applications, the panel will present their final recommendations in June for grants that will begin in October.
We look forward to releasing the names and projects of the winners of The New Grant Award later this year.
No comments:
Post a Comment